ARTICLE | Company News
FDA accepts NDA for menopause product
November 13, 2012 2:09 AM UTC
FDA accepted for review an NDA from Noven Pharmaceuticals Inc. for low-dose paroxetine mesylate to treat vasomotor symptoms associated with menopause. The PDUFA date is June 28, 2013. FDA's Reproducti...